Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mustang Bio Inc (MBIO) and Genomic Health (GHDX).
Mustang Bio Inc (MBIO)
In a report released today, Mark Breidenbach from Oppenheimer maintained a Buy rating on Mustang Bio Inc, with a price target of $18. The company’s shares closed yesterday at $4.09.
Breidenbach noted:
“Wednesday, Mustang announced a new research and licensing agreement with for rights to C134, a second generation HSV1-derived oncolytic virus (OV) for the treatment of glioblastoma multiforme (GBM). 1 development as a monotherapy, we believe C134 could be deployed alongside to improve efficacy in GBM. In our view, OVs could offer an edge to strengthen Mustang’s bid to make CAR-Ts a viable treatment option for solid tumors. With a growing pipeline of in-licensed cell and gene therapies, in-house manufacturing expertise and capabilities, and a deeply discounted market capitalization relative to its peers, we believe Mustang remains an overlooked opportunity. Mustang aims to initiate its first company-sponsored trial by mid-year. $18 PT.”
According to TipRanks.com, Breidenbach is a 1-star analyst with an average return of -2.0% and a 39.4% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Alpine Immune Sciences Inc, and Global Blood Therapeutics.
Mustang Bio Inc has an analyst consensus of Moderate Buy, with a price target consensus of $18.
See today’s analyst top recommended stocks >>
Genomic Health (GHDX)
In a report released today, Kevin Degeeter from Oppenheimer maintained a Hold rating on Genomic Health. The company’s shares closed yesterday at $83.66, close to its 52-week high of $92.18.
Degeeter observed:
“On 2/20/19, GHDX reported healthy 4Q18 growth and 2019 revenue guidance above consensus, but signaled a likely deceleration of growth beginning in 2H19. The outlook is generally in line with our thesis for slowing growth as the impact of TAILORx annualizes beginning in 3Q19 but the base revenue run rate is above our prior forecast. As such, we are increasing our 2019 revenue forecast from $434.8M to $441.9M. While we acknowledge our cautious stance for top-line growth was too early, in our view, 2019 outlook for 11-14% (decelerating potentially into high single digits in 2H19) does not support material multiple expansion beyond current 2.7X 2019 estimates.”
According to TipRanks.com, Degeeter is a 4-star analyst with an average return of 15.8% and a 50.6% success rate. Degeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences Inc, Molecular Templates Inc, and Neon Therapeutics Inc.
Genomic Health has an analyst consensus of Moderate Buy, with a price target consensus of $90.50, an 8.2% upside from current levels. In a report released today, Piper Jaffray also maintained a Hold rating on the stock with a $86 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
